E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin

β-Lactams Increase the Antibacterial Activity of Daptomycin against Clinical Methicillin-Resistant Staphylococcus aureus Strains and Prevent Selection of Daptomycin-Resistant Derivatives

“…For instance, increasing the DAP dose to 10 mg/kg daily overcomes resistance selection both in vitro and in animals infected with S. aureus (1,35). In humans, DAP doses up to 12 mg/kg (for 14 days) appear to be well tolerated, and their use may reduce the risk of resistance in deep-seated or complex infections (6,8). However, the safety profile with prolonged high-dose therapy is not well-known.…”

Safety of High‐Dose Intravenous Daptomycin Treatment: Three‐Year Cumulative Experience in a Clinical Program

“…To date, there are limited safety data for clinical use of daptomycin in doses 16 mg/kg [4][5][6][7][8][9][10][11]. In general, daptomycin is well tolerated, with few significant adverse events other than CPK level elevation.…”

In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin

“…For instance, increasing daptomycin doses to 10 mg/kg daily was shown to overcome resistance selection both in vitro and in animals with S. aureus or vancomycinresistant enterococcal endocarditis [11,12]. In humans, daptomycin doses up to 12 mg/kg for 14 days appear to be well tolerated [13,14] and could reduce the risk of resistance in deep-seated or complex infections. However, the safety profile with prolonged high-dose therapy is not well known.…”